A judge said Friday that he planned to approve a deal for OxyContin maker Purdue Pharma and members of the Sackler family who ...

In our news wrap Friday, a federal bankruptcy judge will approve Purdue Pharma’s latest deal to settle lawsuits over the ...

Fintel reports that on November 13, 2025, D. Boral Capital maintained coverage of Medicus Pharma (NasdaqCM:MDCX) with a Buy recommendation. Analyst Price Forecast Suggests 916.96% Upside As of ...

While AI has accelerated drug discovery, the same technology can address clinical trial bottlenecks that have persisted for ...

NEW DELHI : The Centre has extended the deadline for applying for the ₹ 5,000-crore Promotion of Research and Innovation in ...

OxyContin maker Purdue Pharma, blamed for helping to fuel a deadly opioid crisis, said Friday that a US bankruptcy judge will ...

Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH ...

Strategic process -- Formal engagement with Evercore concluded; current focus is on Phase III clinical execution, with ...

Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...

Pfizer officially buys Metsera; Zealand halts early obesity drug; ESPN, Zepbound and the twilight of the middleman.

A strategic and financial recalibration on psychiatric drug development brings profound implications for investors, insurers, ...

Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently put under a microscope. Cramer said that “you’d do very well” owning the stock, as he stated: “If you want to venture beyond what ...